Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624559 | 0.93 | ITGB1 (0.54) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL3318953 | 0.92 | ITGB1 (0.55) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL4652931 | 0.92 | ITGB1 (0.55) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL3313181 | 0.84 | ITGB1 (0.66) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL4625262 | 0.84 | ITGB1 (0.66) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL3316562 | 0.82 | ITGA4 (0.60) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL4626449 | 0.81 | ITGB1 (0.54) | ITGB1ITGAVAVPR1AITGA4ITGB7 | |
| SCHEMBL4625521 | 0.79 | ITGB1 (0.49) | ITGB1ITGAVITGA4ITGB7CDK2 | |
| SCHEMBL3314959 | 0.79 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7CDK2 | |
| SCHEMBL4624848 | 0.79 | ITGB1 (0.54) | ITGB1ITGAVAVPR1AITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | ITGB1 781/4885ITGAV 425/4885AVPR1A 1052/4885 |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | ITGB1 274/4885ITGAV 65/4885AVPR1A 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.